- Mechanism
- Antagonizes muscular nicotinic acetylcholine receptors
- Typical research dose
- 1-4% concentration in topical formulations
- Route
- topical
- Half-life
- Unknown (topical clearance varies)
- Legal status
- Cosmetic Ingredient / Research Only
Overview
Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate) is a synthetic tripeptide engineered to mimic Waglerin-1, a potent neuromuscular compound found in Temple Viper venom. This topical peptide functions as a competitive antagonist of the muscular nicotinic acetylcholine receptor, effectively relaxing facial muscles to smooth dynamic wrinkles. By offering a non-invasive alternative to injectable neurotoxins, the Syn-Ake peptide has become a highly researched compound in cosmetic science and topical anti-aging formulations.
Potential Benefits
- Dynamic Wrinkle Reduction: Clinical evaluations demonstrate that topical application significantly decreases the appearance of expression lines, particularly crow's feet and forehead wrinkles.
- Targeted Muscle Relaxation: By blocking acetylcholine receptors at the neuromuscular junction, it prevents the repetitive muscle contractions that lead to deep facial creases.
- Non-Invasive Botox Alternative: Offers a topical, needle-free method to achieve localized muscle relaxation without the systemic risks associated with botulinum toxin injections.
- Rapid Onset of Action: In vitro and in vivo studies indicate that muscle relaxation effects can be observed shortly after application, providing fast-acting cosmetic benefits.
- Enhanced Skin Smoothness: Continuous use has been shown to improve overall skin texture and smoothness by reducing the mechanical stress on the epidermal layer.
Side Effects
Common side effects:
- Mild skin irritation at the application site
- Temporary redness or erythema
- Localized tingling sensation
- Dryness or flakiness
- Minor allergic contact dermatitis
Rare or serious side effects:
- Severe allergic reactions or anaphylaxis
- Prolonged facial numbness
- Swelling of the face or eyes
- Disruption of the skin barrier function
Syn-Ake is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.
Mechanism of Action
Receptor antagonism is the primary mechanism by which the Syn-Ake peptide exerts its muscle-relaxing effects. It acts as a reversible, competitive antagonist at the muscular nicotinic acetylcholine receptor (mnAChR) located at the neuromuscular junction. By binding to the epsilon subunit of this receptor, the peptide prevents the binding of acetylcholine, thereby inhibiting the opening of the ion channel and blocking the influx of sodium ions necessary for muscle depolarization.
Inhibition of muscle contraction directly follows this receptor blockade, keeping the facial muscles in a relaxed state. Because the muscle cannot contract in response to nerve impulses, the overlying skin remains smooth, preventing the formation and deepening of dynamic wrinkles. This localized mechanism closely mimics the paralytic action of natural Waglerin-1 but is synthesized to be safe, reversible, and suitable for topical cosmetic application.
Origin & History
Discovery and development of Syn-Ake began when researchers at Pentapharm isolated and studied Waglerin-1 from the venom of the Temple Viper (Tropidolaemus wagleri). Recognizing the cosmetic potential of its muscle-paralyzing properties, scientists synthesized Dipeptide Diaminobutyroyl Benzylamide Diacetate as a smaller, stable, and safer mimetic. This synthetic tripeptide was specifically engineered for optimal skin penetration and topical efficacy, winning the Swiss Technology Award in 2006 for its innovative approach to anti-aging.
Regulatory status classifies Syn-Ake primarily as a cosmetic ingredient rather than a therapeutic drug. It is widely approved for use in topical skincare formulations globally, though it remains designated as research-only in certain clinical contexts evaluating its broader pharmacological potential. As a non-prescription cosmetic peptide, it does not require FDA approval for topical anti-aging applications, provided it makes no structural or functional medical claims.